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Background: Although pain is frequently experienced by patients with cancer, it remains under-treated. The
primary aim of this study was to estimate the prevalence of cancer-related neuropathic pain (CRNP) in patients with
chronic pain who attended an outpatient clinic for standard care in Europe (irrespective of the reason or stage of
the cancer). The secondary aims of this study were to characterise pain and cancer in patients with CRNP (including
treatment) and to evaluate the usefulness of the painDETECT (PD-Q) screening tool to help physicians identify a
potential neuropathic component of cancer-related pain.
Methods: An observational, non-interventional, cross-sectional, multi-centre study of adult patients with cancer
using patient and physician case report forms (CRFs). Patients with CRNP were identified by physicians’ clinical
assessments after examining the completed PD-Q.
Results: A total of 951 patients visiting outpatient clinics across Europe were enrolled in this study between August
2010 and July 2011. Of these, 310 patients (32.60%; 95% confidence interval 29.62, 35.58) were identified as having
CRNP. Twenty-nine of 39 (74.4%) physicians who completed the CRF relating to the PD-Q considered it a useful tool
to help detect CRNP in daily practice and 28 of 39 (71.8%) indicated that they would use this tool in the future for
most or some of their patients. Data from physicians before and after review of the completed PD-Qs showed a
shift in clinical opinion (either to positive CRNP diagnosis [yes] or negative CRNP diagnosis [no]) in respect of 142
patients; about half of which (74) were categorised with an initial diagnosis of unknown. Opinions also shifted from
a no to a yes diagnosis in 10 patients and from a yes to a no diagnosis in 51 patients.
Conclusions: Approximately one-third of adults with cancer experiencing chronic pain attending outpatient
clinics as part of routine care were considered to have CRNP in the opinion of the physicians after considering
scores on the PD-Q. While physicians did not consider the PD-Q to be a useful tool for all patients, shifts in diagnosis
before and after the use of this tool indicate that it may help physicians identify CRNP, especially where there is
initial uncertainty.
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There were an estimated 3.2 million new cases of cancer
and 1.7 million cancer-related deaths in Europe in 2008
[1]. A systematic review of the prevalence of pain in pa-
tients with cancer was estimated at >50% (when cancer
types were pooled); the highest prevalence of pain was
reported in patients with head/neck cancer (70%; 95%
confidence interval [CI] 51%, 88%) [2].* Correspondence: cgrodriguez@iconcologia.net
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distribution, and reproduction in any mediumAlthough pain is frequently experienced by patients
with cancer, it can remain under-treated [3,4] as a result,
in part, of patients’ reluctance to report pain or to take
treatment for pain relief in addition to cancer treatment
[5,6]. Under-treatment can also be caused by a limited
knowledge and practice of the treatment of pain among
oncologists [5,6].
Identifying the type and source of pain in patients
with cancer is complex. Sources of cancer pain vary
from direct tumour invasion of bone, nerves, liga-
ments, etc.; metastasis of the disease; or side effects ofed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mately 33% of cancer survivors were reported to ex-
perience continued pain [2]. Complex chronic pain
syndromes can arise either from surgery, co-morbid
conditions, recurrent cancer and/or treatment [8,9].
Cancer-related pain can either be nociceptive (musculo-
skeletal, cutaneous or visceral) or neuropathic. Neuro-
pathic pain is defined by the International Association for
Study of Pain as “pain caused by a lesion or disease of the
somatosensory nervous system” [10]. Patients can experi-
ence nociceptive and neuropathic pain at the same time
[11,12]. Establishing the nature of the pain in patients
with cancer is key in providing effective pain relief be-
cause particular analgesics do not effectively manage both
neuropathic and nociceptive pain. Between 19% and 39%
of patients with cancer are believed to experience pain
with a neuropathic component, many of whom experience
a mixed pain condition [4]. Neuropathic cancer pain is as-
sociated with poorer physical, cognitive and social func-
tioning and greater requirements for pain medications
than nociceptive cancer pain [13]. Finding effective tools
to enable physicians to better identify cancer-related
neuropathic pain (CRNP) in an outpatient setting would
therefore allow a greater number of patients to receive ef-
fective treatment for CRNP.
In the current study, in addition to physician assess-
ment of neuropathic cancer pain, we used the painDE-
TECT questionnaire (PD-Q), a validated screening tool
that demonstrated high sensitivity and specificity for the
detection of neuropathic pain (85% and 80%, respect-
ively). [13,14]. The PD-Q is an easy-to-use, self-reported
questionnaire that is available in a variety of languages.
The primary objective of this non-interventional study
was to estimate the prevalence of CRNP in patients with
cancer that experienced chronic pain and attended out-
patient oncology clinics and palliative care services in Eur-
ope. The secondary objectives of this study were to
calculate the prevalence point estimate of chronic cancer
pain. The usefulness of the PD-Q screening tool [14] also
was assessed as an aid for physicians to identify the neuro-
pathic component of cancer-related pain. A further object-
ive was to describe the characteristics and impact of pain
and cancer in outpatients experiencing neuropathic pain.
Methods
Study design
This was an observational, non-interventional, cross-
sectional, multi-centre study of adult patients with can-
cer experiencing chronic pain. The study was conducted
between 23 August 2010 and 22 July 2011 in outpatient
oncology clinics in Denmark, Germany, Greece, Spain
and the UK. One of the clinics in Spain was a palliative
care clinic. Data from 63 physicians from 49 sites were
collected in one consultation only (no follow-up) whenpatients visited the doctor as part of standard practice.
Data regarding diagnosis and disease management were
collected retrospectively. Where appropriate, the proto-
cols were reviewed and approved by institutional review
boards/independent ethics committees at participating
sites. Denmark had general permission to conduct non-
interventional studies from the Danish Data Protection
Agency (Datatilsynet) and did not need approval by the
Danish Medicines Agency/Ethics Committee.
Participants
Participants were adults aged ≥18 years who had chronic
cancer-related pain (defined as pain most days of the
week for ≥3 months), attended the oncology unit for an
outpatient consultation (irrespective of the reason or the
stage of the cancer) and were willing to provide in-
formed consent. Patients with chronic pain that was be-
lieved by the physician to be unrelated to cancer were
excluded from the study.
Study enrolment
To obtain a representative sample of the oncology out-
patient population seeking treatment for chronic pain in
Europe, patients who attended oncology clinics from
several centers in selected European counties were re-
cruited. There was a flexible recruitment period to allow
each physician to consecutively enrol up to 20 patients
with chronic pain. In order to minimize any potential re-
cruitment bias, identification and recruitment of patients
eligible for the survey was consecutive. Each and every
patient attending the outpatient clinic was considered
for participation in the survey at the time that the pa-
tient consulted the doctor. In general, prevalence is cal-
culated by dividing the number of individuals with a
certain condition at a particular time point by the total
number of individuals seen. It is therefore important to
ensure that the inclusion of suitable patients by the doc-
tor following recruitment of the first patient is consecu-
tive, in order to estimate a valid prevalence of chronic
pain in patients attending oncology clinics as well as the
prevalence of CRNP in this population. The time of re-
cruitment was recorded for all patients included in the
survey and the prevalence was then calculated. The
protocol was amended in May 2011 to allow the contin-
ued recruitment of patients by an additional physician at
the same site (up to a maximum of 40 patients, with
sponsor permission) if a particular physician was no lon-
ger able to participate in the study.
Eligible participants were identified and screened for
chronic pain (defined in the Participants section above) by
study physicians during consecutive appointments to min-
imise potential recruitment bias (i.e. every patient visiting
the oncologist during the recruitment period was consid-
ered for participation in the study). A screening log was
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outpatient-basis during the consecutive screening and en-
rolment period. As some patients attending the clinics
may have been receiving pharmacological treatment to
manage their pain, the screening log also was intended to
enable physicians to identify which patients would have
been experiencing chronic pain had their pain not been
effectively managed with pharmacological treatment.
Study procedures
A summary of the study procedure is shown in Figure 1.
Eligible participants enrolled in the study completed the
PD-Q, which was used in conjunction with physician as-
sessment to identify patients with chronic pain who also
experienced CRNP [14]. Patients with CRNP were iden-
tified based on the clinical opinion of the physicians be-
fore and after considering scores on the PD-Q.
Physicians and patients with CRNP completed case re-
port forms (CRFs) to record the characteristics of cancer
and pain in the CRNP population. Questions on the CRFs
related to the history and therapeutic management of can-
cer (types of intervention, since time of diagnosis) and
neuropathic pain (duration, aetiology, pharmacologicalFigure 1 Procedure flow.treatment/s for pain, etc.). Patients with CRNP also com-
pleted a series of self-reported questionnaires and rating
scales to assess the impact of their symptoms and pain.
After all patients completed the study, physicians were
asked to complete a physician-specific CRF relating to
the usefulness and future use of the PD-Q and preva-
lence data.
painDETECT questionnaire (PD-Q)
The PD-Q is a validated screening tool [14] developed to
assess the characteristics, persistency, frequency and lo-
cation of presenting pain on numerical scales.
Patients responded to three preliminary questions that
did not contribute to the PD-Q end score to document
the intensity of their pain using a 0–10 rating scale.
The description of pain (persistent with slight fluctua-
tions [score = 0], persistent with pain attacks [score = 1],
or pain attacks without pain between them [score = 1])
was recorded along with the presence (score = 2) or ab-
sence (score = 0) of radiating pain.
The nature of pain was assessed in a series of seven ques-
tions (e.g. is light touching [clothing, a blanket] in this area
painful? Do you suffer from a burning sensation [e.g.
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corded on a 0–5 rating scale (never = 0, hardly noticed = 1,
slightly = 2, moderately = 3, strongly = 4, very strongly = 5).
PD-Q scores relating to the description and presence
of radiating pain (maximum score of 3) and the nature
of pain (maximum score of 35) were summated into a
maximum PD-Q end score of 38. Higher end scores in-
dicated a greater likelihood of neuropathic pain (end
scores <13 = unlikely, 13–18 = possible, >18 = likely).
modified Brief Pain Inventory Short Form (m-BPI-sf)
The severity and interference of pain was assessed via
the self-reported numeric rating scales (range, 0–10) of
the m-BPI-sf [15].
EuroQoL Health Questionnaire (EQ-5D)
Health-related quality of life was assessed in relation to:
mobility, self-care, usual activities, pain/discomfort, anx-
iety or depression on a three-point response scale of the
EQ-5D Health Questionnaire [16] combined into a sin-
gle index utility score (range, 0–1). Patients’ own percep-
tion of their health (how good or bad) also was assessed
on this questionnaire via a self-reported numeric rating
scale (health state score; range, 0–100).
The Sheehan Disability Scale (SDS)
The level of functional impairment in relation to work
or school, social life and home life and family responsi-
bilities was recorded on the SDS [17] using self-reported
10-point visual analogue scales and summated into a
global functional impairment score (maximum 30 =
highly impaired). Patients also recorded the number of
lost and underproductive days of work during the past
week on this form.
Outcome measures
The primary endpoint was the proportion of patients ex-
periencing chronic pain that were considered to have
CRNP in the clinical opinion of the physicians following
an examination of the completed PD-Q.
The point estimate of the proportion of participants ex-
periencing chronic pain was calculated from the total num-
ber of participants screened. However, owing to design
flaws in the screening log, the information relating to pa-
tients whose chronic pain was controlled with pain medica-
tions was not reliably transferred to the physician-specific
case report form (CRF). Consequently, the chronic pain
calculations excluded patients who did not meet the
chronic pain criteria owing to the use of pain medications.
Other secondary endpoints included a description of the
nature, characteristics and management of cancer and pain
in patients with CRNP and the percentage of cancer spe-
cialists who found the screening tool a useful instrument to
identify chronic neuropathic pain in daily practice.Statistical analysis
Sample size and study populations
The projected sample size was changed from approxi-
mately 3900 patients to at least 800 patients in May 2011
owing to difficulty finding sites and physicians who were
willing to take part. However, a sample size of at least 800
patients was still estimated to reliably identify the primary
endpoint (prevalence of CRNP) based on the previously
estimated prevalence of 39.7% [18]. The pre-defined study
populations were as follows: 1) the all participants popula-
tion, defined as all those enrolled in the study. 2) the
CRNP population, defined as those patients identified as
experiencing neuropathic pain in the clinical opinion of
the physicians after examining scores on the PD-Q; and
3) the surveyed physicians population, defined as those
physicians who completed the physician-specific CRF.
Data analysis
Data used to estimate the prevalence of CRNP for all
participants enrolled had an estimated precision of 0.03
(3%; using a 95% CI). Continuous endpoints were sum-
marised using descriptive statistics and discrete end-
points were summarised using frequency and percentage
calculations for each response category (missing data
were excluded from the percentage calculations).
Results
Patient and surveyed physician populations
A total of 951 patients were enrolled in the study and
937 (98.5%) patients completed all or part of the study
(Figure 1). Four (0.4%) patients withdrew during the
screening phase as they were no longer willing to par-
ticipate in the study. Data for 10 (1.1%) patients were ei-
ther missing owing to an entirely missing CRF or a
missing final status page from the CRF.
A total of 63 physicians enrolled patients for the
study; 39 of these also completed the physician-specific
CRF (Figure 1).
Missing data resulting from the missing CRFs or miss-
ing CRF pages in this study are reported for each of the
endpoints in the relevant sections or tables.
Patient demographics
The age ranges of the all participants population are
shown in Table 1. Male participants were slightly older,
on average, than female participants.
Primary endpoint
Of the 951 patients identified to have chronic pain, 310
patients were considered to experience CRNP in the clin-
ical opinion of the physicians after examining scores on
the PD-Q. Thus, the prevalence of CRNP (primary end-
point) was 32.6% (95% CI 29.62, 35.58). The number of
patients considered to experience CRNP by the physicians
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32.19, 38.26). The sex and ages of patients with CRNP
were proportionally similar to the all participants popula-
tion (Table 1).
Secondary endpoints
Prevalence of chronic pain
Data from physicians invited to take part in the study
who did not record the number of patients screened
were not included in the prevalence of chronic pain ana-
lysis. The number of patients included in the chronic
pain calculation differed from the 951 patients identified
for calculating the primary end point. Of 5882 patients
screened by 39 physicians (and for whom screening was
documented), 583 met the criteria for chronic pain and
were enrolled in the study and 172 patients met the cri-
teria and declined participation (Figure 1). The preva-
lence point estimate of chronic pain was therefore
calculated at 12.8% using the following equation:
583þ 172ð Þ 100=5882ð Þ ¼ 12:8%
Nature and treatment of neuropathic pain in patients
with CRNP
In the physicians’ assessment of the type of chronic
cancer-related pain, 100 (32.3%) patients were consid-
ered to have pure neuropathic cancer-related pain and
146 (47.1%) patients were considered to have mixed
cancer-related pain with a neuropathic component. Data
were missing for 64 (20.6%) patients.
While chronic pain was experienced by all participants
for >3 months, the duration of neuropathic pain in theTable 1 Demographic characteristics of patient populations
Male Female
All participantsa, n 502 432
Age, years, n (%)
18-44 17 (3.39) 39 (9.03)
45-64 189 (37.65) 220 (50.93)
≥65 296 (58.96) 173 (40.05)
Missing data 0 0
Mean (SD) 65.88 (11.34) 60.94 (12.33)
Patients with CRNPa, n 144 155
Age, years, n (%)
18–44 4 (2.78) 20 (12.90)
45–64 60 (41.67) 88 (56.77)
≥65 80 (55.56) 47 (30.32)
Missing data 0 0
Mean (SD) 64.67 (10.31) 58.08 (12.35)
aIncorrect dates of birth were recorded for six patients in the all participants popula
bAge data was missing for three patients in the all participants population and two
CRNP, cancer-related neuropathic pain; SD, standard deviation.CRNP population varied from <3 months to >3 years.
Only 28 (9.0%) patients with CRNP reported having the
pain for <3 months, with the greatest percentage (n = 114;
36.8%) having had the pain for 3–6 months. Fifty-five
(17.7%) patients with CRNP reported having had the pain
for 7–12 months, 45 (14.5%) patients had the pain for
13 months–3 years and 10 (3.2%) patients had the pain
for >3 years. Data were missing for 58 (18.7%) patients.
In the opinion of the physicians, the neuropathic pain
experienced by patients with CRNP was due to the
tumour itself in 197 (63.6%) patients and due to cancer-
treatment in 90 (29.0%) patients. Chemotherapy and sur-
gery were each believed to account for neuropathic pain
in 41 (13.2%) patients, respectively. The most commonly
prescribed therapeutic treatments (previous and current
prescriptions) for neuropathic pain in patients with
CRNP were non-opioid analgesics, a strong opioid and/
or anticonvulsants (Table 2).
Pain-related characteristics of CRNP
Numerical rating scores for patients with CRNP were
higher (indicating worse pain) on average compared with
the all participants group for each of the following three
preliminary PD-Q questions to assess pain: 1) “How
would you assess your pain now, at this moment?”; 2)
“How strong was the strongest pain during the past
4 weeks?”; and 3) How strong was the pain during the
past 4 weeks, on average?” (Table 3).
Mean subscale scores on the m-BPI-sf for the CRNP
population were 5.48 (95% CI 5.17, 5.80, n = 252) for
pain interference and 4.63 (95% CI 4.38, 4.89; n = 256)
for pain severity based on numerical rating scales of 0
(no pain) to 10 (pain as bad as you can imagine). DataParticipants for whom sex was not recordedb Total
11 945
2 (18.18) 58 (6.14)
5 (45.45) 414 (43.81)
1 (9.09) 470 (49.74)
3 (27.27) 3 (0.32)
50.75 (13.05) 63.48 (12.12)
9 308
2 (22.22) 26 (8.44)
4 (44.44) 152 (49.35)
1 (11.11) 128 (41.56)
2 (22.22) 2 (0.65)
50.14 (13.97) 61.00 (12.01)
tion and two patients in the CRNP population.
patients in the CRNP population in those patients whose sex was unknown.
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and pain severity, respectively. Mean scores for individ-
ual items on the m-BPI-sf in the CRNP population were
all between 4.08 and 6.58, with the exception of pain at
its least in last 24 hours (mean = 2.92; Table 4).
Characteristics of cancer and treatment in patients with CRNP
Types and characteristics of cancer The types and
characteristics of cancer in patients with CRNP are sum-
marised in Table 5. The most common types of cancer
in this population were breast cancer (18.1%) and lung
cancer (14.5%). Many (44.2%) patients with CRNP had
loco-regional progression of cancer and approximately
half (49.0%) experienced metastasis of the disease in one
or more site (Table 5). Bone was the most commonly re-
ported site for metastasis (Table 5).
Summary of therapeutic management of cancer The
majority of patients with CRNP had received prior or on-
going chemotherapy (62.6%) and/or radiotherapy treat-
ment (53.9%) at the time of the study (Table 6).
Summary of recorded surgical treatment The recorded
surgical-procedures for patients with CRNP were varied
and included bilateral salpingo-oophorectomy, total ab-
dominal hysterectomy, exeresis, lymphadenectomy and
mastectomy. These procedures were categorised accord-
ing to the nature of the treatment. The number of pa-
tients receiving each categorised treatment are as follows
(patients could have received more than one): neoadju-
vant (cancer treatment given before surgery) = 36
(11.6%) patients; adjuvant (cancer treatment given after
surgery) = 67 (21.6%) patients; advanced/metastatic (sur-
gical removal of parts of the body due to secondary can-
cer) = 29 (9.4%) patients; palliative (surgery to reduceTable 2 Therapeutic management of neuropathic paina in
patients with CRNP
Prescribed treatment for neuropathic pain, Previous Current
n (%) n = 310 n = 310
Non-opioid analgesics 164 (52.90) 123 (39.68)
Weak opioid 62 (20.00) 35 (11.29)
Strong opioid 136 (43.87) 121 (39.03)
Antidepressants 36 (11.61) 29 (9.35)
Anticonvulsants 95 (30.65) 118 (38.06)
Muscle relaxants 11 (3.55) 7 (2.26)
Corticosteroids 44 (14.19) 44 (14.19)
Antispasmodics 2 (0.65) 0
Anxiolytics 41 (13.23) 30 (9.68)
Other 20 (6.45) 23 (7.42)
None 6 (1.94) 22 (7.10)
aMore than one treatment type was possible for each patient.
CRNP, cancer-related neuropathic pain.severity of symptoms, etc.) = 17 (5.5%) patients. Ninety-
five (30.7%) patients were not given surgical cancer
treatments, treatment category data were missing for 39
(12.6%) patients and the surgery CRF page was missing
for 56 (18.1%) patients.Health-related quality of life (QOL) in patients with CRNP
EQ-5D The mean health state score on the EQ-5D [16]
for patients with CRNP was 51.07 (95% CI 48.39, 53.74)
on a scale of 0–100. The mean utility score was 0.53 (95%
CI 0.50, 0.56) on a scale of 0–1, with higher score indicat-
ing better health. Data were missing for 58 and 60 pa-
tients for the health state and utility scores, respectively.SDS The mean total score on the SDS for patients with
CRNP was 18.67 (95% CI 17.50, 19.84) based on func-
tional impairment scales of 0–30 (higher scores indicate
greater impairment). Data were missing for 116 patients.
Mean scores for the individual items on the SDS are
shown in Table 7.Patients’ assessment of disease (CRF)
Of the patients with CRNP, 76 (24.5%) recorded no visits
to the doctor in relation to the management of neuro-
pathic pain over the past 4 weeks, 180 (58.1%) patients re-
corded one visit or more and data were missing for 54
(17.4%) patients (Table 8). One hundred forty-one (45.5%)
patients with CRNP indicated that their symptoms had an
effect on their employment status, while 105 (33.9%) pa-
tients with CRNP indicated that they did not. Data were
missing for 64 (20.6%) patients (Table 8). The majority
(74.8%) of patients with CRNP reported having used pre-
scription medications over past 4 weeks (Table 8).Physicians’ evaluation of the PD-Q
Twenty-nine (74.4%) of the surveyed physician population
(n = 39) responded yes to the question: “Did you find the
painDETECT Questionnaire useful?” Seven of the other
10 physicians responded no and there were missing data
for the remaining three physicians. For the question “Did
the painDETECT Questionnaire help you evaluate if you
think the patient has CRNP?”, of the patients identified to
have chronic pain (n=951), physicians responded yes for
334 (35.1%) individual patients and no for 579 (60.9%) pa-
tients. Data were missing for 38 (4.0%) patients.
In response to the question “In future would you use
the painDETECT Questionnaire?”, none of the physicians
indicated that they would use it for all of their patients, 13
(33.3%) indicated that they would for most patients, 15
(38.5%) for some patients and four (10.3%) for a few pa-
tients. Five (12.8%) physicians indicated that they would
not use it. Data were missing for two physicians.
Table 3 Patients’ assessment of pain: painDETECT scale 0 (no pain) to 10 (maximum pain)
Question Patients with CRNP All participants
n = 310 n = 951
How would you assess your pain now, at this moment? Mean (SD) 4.36 (2.58) 3.74 (2.55)
95% CI 4.07, 4.65 3.57, 3.90
Missing data, n 4 22
How strong was the strongest pain during the past 4 weeks? Mean (SD) 7.94 (1.96) 7.23 (2.40)
95% CI 7.72, 8.16 7.08, 7.39
Missing data, n 3 20
How strong was the pain during the past 4 weeks, on average? Mean (SD) 5.55 (2.00) 4.97 (2.06)
95% CI 5.33, 5.78 4.83, 5.10
Missing data, n 4 24
CI, confidence interval; CRNP, cancer-related neuropathic pain; SD, standard deviation.
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assessment
Of the three scoring categories on the PD-Q, the great-
est number of patients diagnosed with CRNP scored >18
(likely), followed by scores of 13–18 (possible); the few-
est number of patients diagnosed with CRNP scored <13
(unlikely). The opposite trend was apparent in patients
without a diagnosis of CRNP (Figure 2).
The shifts in the numbers of patients to either a positive
or a negative diagnosis of CRNP following physicians’
examination of the PD-Q (distributed by PD-Q end
scores) are shown in Figure 3. For 142 patients, the diag-
nosis shifted after an examination of the PD-Q; about half
(74) of which were previously categorised as unknown.
Shifts in patients with a low PD-Q score (<13) were most
likely to move towards not having CRNP (93/99), whereas
patients with scores >18 (although less in absolute num-
bers) were more likely to shift towards having CRNP (10/
13) in the clinical opinion of the physician. Of the 51 pa-
tients who shifted from yes to no, only one (2.0%) had aTable 4 Summary of self-reported pain m-BPI-sf scales 0 (no p
n M
Sub-questions of severity scale
Pain on average in last 24 hours 256 4
Worst pain in last 24 hours 256 6
Pain right now 256 4
Pain at its least in last 24 hours 256 2
Sub-questions of interference scale
General activity 256 5
Mood 256 5
Walking ability 256 4
Normal work 254 6
Relations 255 4
Sleep 255 5
Enjoyment of life 256 5
CI, confidence interval; CRNP, cancer-related neuropathic pain; m-BPI-sf, modified BPD-Q score >18 and of the 10 patients who shifted from
no to yes, four (40.0%) patients had a PD-Q score >18.
Discussion
A total of 951 patients experiencing chronic pain who
visited oncology clinics across Europe were enrolled in
this study. Approximately 94% of these patients were
≥45 years of age and the ratio of male to female partici-
pants was approximately 1.2:1.0. Of the 951 patients
with chronic pain, 310 were identified as having CRNP
in the opinion of the participating physicians after evalu-
ating the PD-Q. The primary endpoint of this study, the
proportion of patients with CRNP in patients with can-
cer experiencing chronic pain, was therefore 32.6% (95%
CI 29.62, 35.58). The percentage of patients with CRNP
identified in this study was in line with the international
study estimation of 39.7% [18] and within the range
of estimates reported in a recent review of studies of
neuropathic pain in patients with cancer, which varied
from 19% to 39% [4].ain) to 10 (maximum pain) in patients with CRNP
ean (SD) 95% CI Missing data, n
.96 (2.12) 4.70, 5.22 54
.58 (2.61) 6.26, 6.90 54
.08 (2.66) 3.75, 4.41 54
.92 (2.20) 2.65, 3.19 54
.91 (3.03) 5.53, 6.28 54
.69 (3.02) 5.32, 6.06 54
.98 (3.43) 4.55, 5.40 54
.35 (3.16) 5.96, 6.74 56
.55 (3.27) 4.15, 4.95 55
.04 (3.34) 4.62, 5.45 55
.86 (3.29) 5.46, 6.27 54
rief Pain Inventory Short Form; SD, standard deviation.
Table 5 Summary of characteristics and type of cancera in
patients with CRNP
Characteristic n = 310






Missing data 55 (17.74)
Loco-regional progression of the cancer, n (%)
Yes 137 (44.19)
No 104 (33.55)
Missing data 69 (22.26)




Lymph node 77 (24.84)
Liver 40 (12.90)
Other 42 (13.55)
Missing data 117 (37.74)









Missing data 123 (39.68)
aA single patient could have more than one primary diagnoses.
bOther cancer types included: sarcoma, myeloma, cervical, pancreatic, renal,
bladder, endometrial and head and neck cancer as well as other MedDRA
lowest level term types of cancer, including unknown primary cancer.
cFor site of metastasis more than one response was possible.
CRNP, cancer-related neuropathic pain; MedDRA, Medical Dictionary for
Regulatory Activities.


























aMore than one treatment type was possible for each patient.
bChemotherapy treatment included platinum compounds, vinca alkaloids,
taxanes, antimetabolites and nitrosoureas among others and treatment could
have been before or ongoing at the time of the study.
CRNP, cancer-related neuropathic pain.
Table 7 Individual items of the Sheehan Disability Scale
n Mean (SD) 95% CI Missing data, n
Work/school 194 6.74 (3.02) 6.31, 7.17 116
Social life 252 5.94 (3.11) 5.56, 6.33 58
Family life 252 5.90 (2.99) 5.53, 6.27 58
Days lost 208 4.34 (4.63) 3.71, 4.97 102
Days unproductive 206 3.83 (3.03) 3.41, 4.24 104
CI, confidence interval; SD, standard deviation.
Garzón-Rodríguez et al. BMC Palliative Care 2013, 12:41 Page 8 of 12
http://www.biomedcentral.com/1472-684X/12/41Variations in estimates of CRNP may reflect different
populations or stages of cancer. In this study, the percent-
age of patients with CRNP was determined from a sample
of adult oncology outpatients experiencing chronic pain.
The outpatients with CRNP included in the study pre-
sented with varied characteristics and stages of cancer;
some experienced loco-regional progression and/or me-
tastasis of the tumour (as shown in the CRNP popula-
tion), while others had early stage cancer or were cancer
survivors. However, the study results are limited by miss-
ing data and cannot be generalised to the cancer patient
populations as a whole.Based on available data from the 5882 screened pa-
tients, the prevalence point of chronic pain in patients
with cancer was estimated at 12.8%. This calculation is
lower than previous estimates of chronic pain in patients
with cancer at various stages of the disease (including
patients who received curative treatment as well as those
with advanced stages of the disease) [2]. Reasons for the
lower prevalence rate in the current study are not
known, but may have been influenced by the criteria for
chronic pain that excluded patients who had experi-
enced chronic pain for <3 months or by the screening
Table 8 Patients with CRNP: assessment of disease
Items on patient CRF Patients with CRNP n = 310






Missing data 54 (17.42)
Symptom effect on employment status
Missing data 64 (20.65)
No 105 (33.87)
Yes 141 (45.48)
Reduced normal life 43 (13.87)
Disabled 56 (18.06)
Unemployed or retired earlier than expected 34 (10.97)
Missing data 8 (2.58)
Treatment used over past 4 weeksa
None 8 (2.58)
Prescription medications 232 (74.84)
Non-prescription medications 27 (8.71)
Physiotherapy 15 (4.84)
Massage 14 (4.52)
Other treatments 23 (7.42)
aPatients could give more than one response to this question.
CRF, case report form; CRNP, cancer-related neuropathic pain.
Figure 2 Distribution of participants by PD-Q end scores according to CRNP or non-CRNP diagnosis.
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Figure 3 Switch to a negative (a) or positive (b) diagnosis of CRNP, by PD-Q end score.
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was effectively controlled by pain medication. The
screening log was intended to enable physicians to iden-
tify patients that would have been experiencing chronic
pain had they not been receiving pain medications to ef-
fectively manage their pain. However, reliably identifying
such patients required a complex process, requiring phy-
sicians to transfer a particular combination of responses
from the screening log to the physician-specific CRF.
Missing data, time-constraints and/or oversights resulted
in unreliable recording of the number of patients that
did not meet the criteria for chronic pain owing to the
use of pain medications; therefore, for the purpose of
the chronic pain calculations, such patients were ex-
cluded. In the opinion of the authors, the number of pa-
tients for whom this situation applied would have had
little impact on the prevalence point estimate of chronic
pain (an underestimation). Some patients also may have
failed to report their pain. For example, cancer survivors
sometimes fail to acknowledge or report chronic pain
because of concerns related to the long-term use of
pain-medications [19]. Other reasons that patients with
cancer fail to report pain include the desire to be a good
patient, a concern that pain is an indication of disease
progression, a belief that their physician should focus on
treating the cancer rather than the pain or a fear of ad-
diction and/or side effects of pain medications [6,20].
Some of the patients with CRNP may have been expe-
riencing chemotherapy-induced peripheral neuropathy
(CINP), which has been documented to cause a diagnos-
tic dilemma for clinicians owing to the range of toxic
etiologies that may mimic the clinical features of cancer
[21]. Consequently, CINP can go under-reported and
under-treated, and may have thereby contributed to the
low prevalence point estimate of chronic pain [21].
In the CRNP population, mean m-BPI-sf scores were >4
for each of the individual items (scale of 0–10) with the
exception of pain at its least in the last 24 hours (mean =
2.92), indicating that pain in patients with CRNP waseither not being effectively managed or was difficult to
treat. As noted earlier, there have been reports of general
under-treatment of pain in patients with cancer [3,6]. In
part, this may be a result of higher priority given to cura-
tive treatment compared with effective pain relief or an
inadequate knowledge of pain management; for example
not tailoring treatment to the specific type of pain [6,20].
In a recent survey conducted in the United States, oncolo-
gists identified poor pain assessment as the greatest bar-
rier to managing pain effectively [5].
Average higher scores for each of the three PD-Q pain
assessment questions in patients with CRNP compared
with the all participants population may indicate that
CRNP is more difficult to identify and/or treat effectively
than chronic pain without a neuropathic component and
that physicians may traditionally choose analgesics pri-
marily effective on nociceptive pain as first-line pain
treatment. Indeed, patients with CRNP self-reported
mean scores on the EQ-5D and SDS indicated that their
symptoms of pain had a negative impact on many as-
pects of daily functioning and quality of life. Moreover,
45.5% of patients with CRNP indicated that their symp-
toms had an effect on their employment status, thus
highlighting the need for future randomised controlled
trials to establish the most effective treatment for neuro-
pathic pain relief within cancer outpatient settings.
The World Health Organization (WHO) guidelines for
cancer pain relief state that it is necessary to evaluate the
type and level of pain experienced by patients with cancer
in order to treat it effectively [22]. In addition to local an-
aesthetic congeners and/or opioids to treat neuropathic
pain or mixed nociceptive and neuropathic pain, the WHO
guidelines list tricyclic antidepressants and anticonvulsants
as recommended treatments [22]. The European Society
for Medical Oncology clinical practice guidelines recom-
mend the treatment of neuropathic pain with both opioid
and non-opioid analgesics, in particular tricyclic antidepres-
sants (amitriptyline) or anticonvulsants (gabapentin) [23].
Radiotherapy is recommended for neuropathic pain due to
Garzón-Rodríguez et al. BMC Palliative Care 2013, 12:41 Page 11 of 12
http://www.biomedcentral.com/1472-684X/12/41bone metastases [23]. The European Federation of Neuro-
logical Societies Task Force guidelines for neuropathic pain
assessed the evidence for gabapentin as a treatment for
CRNP as level A and amitriptyline and tramadol as level B
(based on a single study) [24]. A recent review of treat-
ments for cancer pain listed multi-purpose analgesics (i.e.
glucocorticoids and tricyclic antidepressants) and the anti-
convulsants gabapentin and pregabalin as effective treat-
ments for neuropathic pain in patients with cancer [25].
The most commonly prescribed treatments for neuro-
pathic pain in the CRNP population in this study were
non-opioid analgesics, a strong opioid and/or anticonvul-
sants. It should be noted that these patients also may have
been receiving more than one therapeutic treatment and/
or demonstrated a mixed pain profile. Of the available data
in the physician study assessments, mixed cancer-related
pain with a neuropathic component was evident in 47.1%
of patients with CRNP and in 32.3% of those with pure
CRNP. Data were missing for 64 (20.6%) patients with
CRNP. Neuropathic pain was considered to be directly due
to the tumour in 63.6% of patients with CRNP and due to
cancer treatment in 29.0%. However, the types and
characteristics of cancer in patients with CRNP in this
study were varied, as were their experiences of thera-
peutic management and surgical treatment of the dis-
ease. These data highlight that neuropathic pain is not
specific to patients with a particular cancer and/or
treatment profile and demonstrate the need to screen
for neuropathic pain in all patients with cancer, regard-
less of the stage or type of disease.
A further objective of this study was to assess the use-
fulness of the PD-Q as a screening tool to help physicians
identify neuropathic pain in patients with cancer. The
usefulness of PD-Q for detecting neuropathic cancer pain
has been previously assessed in comparison to the Ed-
monton Classification System of Cancer Pain (ECS-CP).
Based on their initial categorization of patients as having
a neuropathic component if their PD-Q score ranged
from 13 to 38 (similar to our study) and the comparison
to the ECS-CP, the authors calculated the sensitivity and
specificity of PD-Q for the detection of cancer-related
neuropathic pain as 53% and 77%, respectively [26]. In the
current study, the distribution of patients with and with-
out a diagnosis of CRNP according to the PD-Q end-
scores was largely in keeping with the physicians’ assess-
ment of the likelihood that a patient is experiencing
neuropathic pain. There is evidence that the use of the
PD-Q changed physicians’ clinical opinions in some cases,
in particular, the shift to a diagnosis of not having CRNP
for patients with PD-Q end scores of <13. Many patients
for whom physicians changed their initial opinion to a
positive diagnosis of CRNP were those whose diagnosis
was recorded as unknown before evaluation of the PD-Q.
Thus, the PD-Q may be a useful tool to help identifyCRNP in situations in which physicians are initially
unsure.
The majority (74.4%) of the 39 physicians who com-
pleted the physician-specific CRF indicated that they
found the PD-Q a useful tool to help detect CRNP in
daily practice and over 70% indicated that they would
use this tool to evaluate most, or some, of their patients
in the future. The PD-Q was initially developed to iden-
tify neuropathic pain in patients with back pain as a
model for mixed pain conditions [14], and, as with many
other screening tools, it has not been exclusively vali-
dated for use in patients with cancer. However, these re-
sults suggest that the PD-Q may be a useful screening
tool for CRNP.
As with all non-interventional studies, there are par-
ticular advantages and limitations of the design of this
study. This large-scale multi-centre study allowed the
opportunity to collect epidemiological data from patients
with cancer across Europe and add to the literature re-
lating to CRNP. The limitations associated with this
study include the difficulties in recruiting investigators
who were willing to participate. This proved more chal-
lenging than anticipated and impacted the enrolment of
participants, thereby leading to a decrease in the
planned sample size. Incomplete or missing CRF forms
also were a consequence of the non-interventional meth-
odology that may have impacted on the overall chronic
pain prevalence estimates, which should therefore be
interpreted with caution.
Conclusions
This observational, non-interventional, cross-sectional,
multi-centre study showed that a proportion of adult pa-
tients with cancer who were attending outpatient clinics
in Europe were experiencing uncontrolled pain and al-
most a third had neuropathic pain. The results of this
study highlight the wide range of patients with cancer ex-
periencing CRNP and emphasise the importance of de-
tecting neuropathic pain in order to treat it effectively.
Screening tools like the PD-Q may help physicians iden-
tify neuropathic pain in patients with cancer for the pur-
poses of effective pain management, which may ultimately
impact the functional ability and quality of life of patients
with CRNP.
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